ArticleMolecular medicine reports2019
Visfatin is regulated by interleukin‑6 and affected by the PPAR‑γ pathway in BeWo cells.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Periodontitis is associated with the increased levels of visfatin: a meta-analysis.BMC oral health · 2023Pooled it
- The Effect of Kidney Transplantation and Immunosuppressive Therapy on Adipose Tissue Content and Adipocytokine Plasma Concentration-Preliminary Study.Current issues in molecular biology · 2025Article
- Status of visfatin in female reproductive function under normal and pathological conditions: a mini review.Molecular biology reports · 2024Review
- Article
- Biomarkers for Diagnosing and Treating Fetal Growth Restriction.Current medicinal chemistry · 2024Review
- Exploring the potential roles of apelin, visfatin, and irisin in energy regulation in farm animals: an overview.Frontiers in veterinary science · 2024Review
- Visfatin and Retinol Binding Protein-4 in Young-Onset Type 2 Diabetes Mellitus.Medicina (Kaunas, Lithuania) · 2023Article
- Recent progress in metabolic reprogramming in gestational diabetes mellitus: a review.Frontiers in endocrinology · 2023Review
- Role of visfatin in obesity-induced insulin resistance.World journal of clinical cases · 2022Review
- Review
- Does C-C Motif Chemokine Ligand 2 (CCL2) Link Obesity to a Pro-Inflammatory State?International journal of molecular sciences · 2021Review
- Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Trophoblast Functions.International journal of molecular sciences · 2021Review
- Adipokines as biomarkers of postpartum subclinical endometritis in dairy cows.Reproduction (Cambridge, England) · 2020Article
- The comparison of visfatin levels of gingival crevicular fluid in systemic lupus erythematosus and chronic periodontitis patients with healthy subjects.Clinical rheumatology · 2019Article
- Involvement of Novel Adipokines, Chemerin, Visfatin, Resistin and Apelin in Reproductive Functions in Normal and Pathological Conditions in Humans and Animal Models.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visfatin, an adipocytokine and cytosolic enzyme with nicotinamide phosphoribosyltransferase (Nampt) activity, is involved in the pathogenesis of numerous metabolic disorders. In addition, the nuclear receptor peroxisome proliferator‑activated receptor‑γ (PPAR‑γ) serves important roles in anti‑inflammatory reactions and regulates glucose and lipid metabolism. The aim of the present study was to investigate the effect of interleukin‑6 (IL‑6) on the expression and secretion of visfatin in BeWo cells, and to determine whether the PPAR‑γ pathway is involved in the regulation of visfatin by IL‑6. Therefore, BeWo cells were stimulated with serial concentrations of IL‑6 or pioglitazone, and the expression levels of visfatin and PPAR‑γ were determined by reverse transcription‑quantitative polymerase chain reaction and western blotting. The results of the present study demonstrated that IL‑6 downregulated the mRNA levels of visfatin and PPAR‑γ, which were strongly associated. Activation of PPAR‑γ by pioglitazone resulted in significantly increased expression of visfatin, which abrogated the inhibitory effect of IL‑6 on visfatin in BeWo cells. Furthermore, treatment using pioglitazone alone increased the expression and secretion of the visfatin protein, compared with the control or IL‑6 alone group. In summary, the findings of the present study suggested that IL‑6 inhibited the expression of visfatin and PPAR‑γ at the transcriptional level; in addition, activation of PPAR‑γ upregulated visfatin at the mRNA and protein expression levels. Therefore, the PPAR‑γ signaling pathway may be involved in the regulation of visfatin by IL‑6 in BeWo cells. These results may provide novel insight into the roles of visfatin in trophoblastic cells. Furthermore, thiazolidinedione pioglitazone, by upregulating visfatin expression, may promote the energy metabolism of trophoblastic cells, maintain the function of the placenta and improve the outcome of pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.